Inhibikase Therapeutics, Sphaera Pharma Pvt. Ltd. and Sphaera Pharma Pte. Ltd. | Date: 2013-10-04
Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.
Dugar S.,Sphaera Pharma Pte. Ltd. |
Sharma A.,Sphaera Pharma Pvt. Ltd |
Kuila B.,Sphaera Pharma Pvt. Ltd |
Mahajan D.,Sphaera Pharma Pvt. Ltd |
And 2 more authors.
Synthesis (Germany) | Year: 2014
A simple and efficient method has been developed for the synthesis of substituted morpholines by a sequence of coupling, cyclization, and reduction reactions of easily available amino alcohols and α-halo acid chlorides. Various mono-, di-, and trisubstituted morpholines, spiro morpholines, and ring-fused morpholines, as well as morpholine homologues, were synthesized in good to excellent yields by a single methodology under similar reaction conditions. The method was also used in a multigram synthesis of (3S)-3-methylmorpholine. Source
Sphaera Pharma Pte. Ltd. | Date: 2013-07-23
The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical acceptable excipients and use of the compounds to modulate the PI3K/mTOR pathway.
Sphaera Pharma Pte. Ltd. | Date: 2012-01-24
The present invention provides synthetic processes for preparing racemic and/or optically pure epicatechin, epigallocatechin and related polyphenols as such or as their variously functionalized derivatives. A principle objective of the disclosure is to provide a new and useful method of synthesis to obtain polyphenols in isomerically pure and/or racemic forms.
Sphaera Pharma Pte Ltd. | Date: 2013-10-07
The present invention discloses novel chemical compounds obtained by causing a covalent attachment of a modifying agent of the structure provided for formula 1, to a functional group or a heteroatom of a heterocyclic ring system in chemical compound with improved chemical and biological properties. Wherein: Y is DRUG-CO; DRUG-OCO; DRUG-NRCO, and X is selected from.